Federal Register / Vol. 65, No. 212 / Wednesday, November 1, 2000 / Notices 65321

compounding, the practices of

pharmacies specializing in

compounding, the practices of general

retail pharmacies, the practices of

hospital pharmacies, fields of medicine

in which compounding drugs or the use

of compounded drugs is relatively

common, pharmaceutical

manufacturing, clinical toxicology,

clinical pharmacology, chemistry, and

related specialties. The current

committee includes one representative

of the NABP, one representative of the

USP, one representative of a consumer

organization, and one representative of

the pharmaceutical manufacturing

industry whose terms have not yet

expired. The term of office is up to 4

years.

Nomination Procedures

Interested persons may nominate one

or more qualified persons for

membership on the advisory committee.

Nominations shall state that the

nominee is willing to serve as a member

of the advisory committee and appears

to have no conflict of interest that

would preclude committee membership.

Potential candidates will be asked by

FDA to provide detailed information

concerning such matters as financial

holdings, consultancies, and research

grants or contracts to permit evaluation

of possible sources of conflict of

interest.

This notice is issued under the

Federal Advisory Committee Act (5

U.S.C. app. 2), section 503A of the

Federal Food, Drug, and Cosmetic Act

(21 U.S.C. 353a), section 904 of the

Federal Food, Drug, and Cosmetic Act

(21 U.S.C. 394) as amended by the Food

and Drug Administration Revitalization

Act (Public Law 101–635), and 21 CFR

part 14, relating to advisory committees.

Dated: October 25, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–27966 Filed 10–31–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be listed at the end, and will be omitted

from the monthly listing thereafter.

This Notice is also available on the

internet at the following website: http:/

/www.health.org/workplace.

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh or Dr. Walter Vogl,

Division of Workplace Programs, 5600

Fishers Lane, Rockwall 2 Building,

Room 815, Rockville, Maryland 20857;

Tel.: (301) 443–6014, Fax: (301) 443–

3031.

Special Note: Please use the above address

for all surface mail and correspondence. For

all overnight mail service use the following

address: Division of Workplace Programs,

5515 Security Lane, Room 815, Rockville,

Maryland 20852.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACL Laboratories, 8901 W. Lincoln

Ave., West Allis, WI 53227, 414–328–

7840/800–877–7016, (Formerly:

Bayshore Clinical Laboratory).

Advanced Toxicology Network, 3560

Air Center Cove, Suite 101, Memphis,

TN 38118, 901–794–5770/888–290–

1150.

Aegis Analytical Laboratories, Inc., 345

Hill Ave., Nashville, TN 37210, 615–

255–2400.

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931/334–263–5745.

Alliance Laboratory Services, 3200

Burnet Ave., Cincinnati, OH 45229,

513–585–9000, (Formerly: Jewish

Hospital of Cincinnati, Inc.).

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

20151, 703–802–6900.

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866/800–433–2750.

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–202–2783

(Formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Clinical Laboratory Partners, LLC, 129

East Cedar St., Newington, CT 06111,

860–696–8115 (Formerly: Hartford

Hospital Toxicology Laboratory)

Clinical Reference Lab, 8433 Quivira

Rd., Lenexa, KS 66215–2802, 800–

445–6917

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652/417–269–3093 (Formerly:

Cox Medical Centers)

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, Building

38–H, P.O. Box 88–6819, Great Lakes,

IL 60088–6819, 847–688–2045/847–

688–4171

Diagnostic Services Inc., dba DSI, 12700

Westlinks Drive, Fort Myers, FL

33913, 941–561–8200/800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31602,

912–244–4468

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

206–386–2672/800–898–0180

(Formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

Dynacare Kasper Medical Laboratories,*

14940–123 Ave., Edmonton, Alberta,

65322 Federal Register / Vol. 65, No. 212 / Wednesday, November 1, 2000 / Notices

Canada T5V 1B4, 780–451–3702/800–

661–9876

ElSohly Laboratories, Inc., 5 Industrial

Park Dr., Oxford, MS 38655, 662–236–

2609

Express Analytical Labs, 1301 18th Ave

NW, Suite 110, Austin, MN 55912,

507–437–7322

Gamma-Dynacare Medical

Laboratories,* A Division of the

Gamma-Dynacare Laboratory

Partnership, 245 Pall Mall St.,

London, ONT, Canada N6A 1P4, 519–

679–1630

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–

267–6267

Integrated Regional Laboratories, 5361

NW 33rd Avenue, Fort Lauderdale, FL

33309, 954–777–0018, 800–522–0232

(Formerly: Cedars Medical Center,

Department of Pathology)

Kroll Laboratory Specialists, Inc., 1111

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823 (Formerly:

Laboratory Specialists, Inc.)

LabOne, Inc., 10101 Renner Blvd.,

Lenexa, KS 66219, 913–888–3927/

800–728–4064 (Formerly: Center for

Laboratory Services, a Division of

LabOne, Inc.)

Laboratory Corporation of America

Holdings, 7207 N. Gessner Road,

Houston, TX 77040, 713–856–8288/

800–800–2387

Laboratory Corporation of America

Holdings, 1904 Alexander Drive,

Research Triangle Park, NC 27709,

919–572–6900/800–833–3984

(Formerly: LabCorp Occupational

Testing Services, Inc., CompuChem

Laboratories, Inc.; CompuChem

Laboratories, Inc., A Subsidiary of

Roche Biomedical Laboratory; Roche

CompuChem Laboratories, Inc., A

Member of the Roche Group)

Laboratory Corporation of America

Holdings, 4022 Willow Lake Blvd.,

Memphis, TN 38118, 901–795–1515/

800–233–6339 (Formerly: LabCorp

Occupational Testing Services, Inc.,

MedExpress/National Laboratory

Center)

Laboratory Corporation of America

Holdings, 69 First Ave., Raritan, NJ

08869, 908–526–2400/800–437–4986

(Formerly: Roche Biomedical

Laboratories, Inc.)

Marshfield Laboratories, Forensic

Toxicology Laboratory, 1000 North

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–331–3734

MAXXAM Analytics Inc.*, 5540

McAdam Rd., Mississauga, ON,

Canada L4Z 1P1, 905–890–2555

(Formerly: NOVAMANN (Ontario)

Inc.)

Medical College Hospitals Toxicology

Laboratory, Department of Pathology,

3000 Arlington Ave., Toledo, OH

43699, 419–383–5213

MedTox Laboratories, Inc., 402 W.

County Rd. D, St. Paul, MN 55112,

651–636–7466/800–832–3244

MetroLab-Legacy Laboratory Services,

1225 NE 2nd Ave., Portland, OR

97232, 503–413–5295/800–950–5295

Minneapolis Veterans Affairs Medical

Center, Forensic Toxicology

Laboratory, 1 Veterans Drive,

Minneapolis, Minnesota 55417, 612–

725–2088

National Toxicology Laboratories, Inc.,

1100 California Ave., Bakersfield, CA

93304, 661–322–4250/800–350–3515

NWT Drug Testing, 1141 E. 3900 South,

Salt Lake City, UT 84124, 801–293–

2300/800–322–3361 (Formerly:

NorthWest Toxicology, Inc.)

One Source Toxicology Laboratory, Inc.,

1705 Center Street, Deer Park, TX

77536, 713–920–2559 (Formerly:

University of Texas Medical Branch,

Clinical Chemistry Division; UTMB

Pathology-Toxicology Laboratory)

Oregon Medical Laboratories, P.O. Box

972, 722 East 11th Ave., Eugene, OR

97440–0972, 541–687–2134

Pacific Toxicology Laboratories, 6160

Variel Ave., Woodland Hills, CA

91367, 818–598–3110/800–328–6942

(Formerly: Centinela Hospital Airport

Toxicology Laboratory)

Pathology Associates Medical

Laboratories, 11604 E. Indiana Ave.,

Spokane, WA 99206, 509–926–2400/

800–541–7891

PharmChem Laboratories, Inc., 1505–A

O’Brien Dr., Menlo Park, CA 94025,

650–328–6200/800–446–5177

PharmChem Laboratories, Inc., Texas

Division, 7606 Pebble Dr., Fort Worth,

TX 76118, 817–215–8800 (Formerly:

Harris Medical Laboratory)

Physicians Reference Laboratory, 7800

West 110th St., Overland Park, KS

66210, 913–339–0372/800–821–3627

Poisonlab, Inc., 7272 Clairemont Mesa

Blvd., San Diego, CA 92111, 858–279–

2600/800–882–7272

Quest Diagnostics Incorporated, 3175

Presidential Dr., Atlanta, GA 30340,

770–452–1590 (Formerly: SmithKline

Beecham Clinical Laboratories,

SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated, 4444

Giddings Road, Auburn Hills, MI

48326, 248–373–9120/800–444–0106

(Formerly: HealthCare/Preferred

Laboratories, HealthCare/MetPath,

CORNING Clinical Laboratories)

Quest Diagnostics Incorporated, 8000

Sovereign Row, Dallas, TX 75247,

214–638–1301 (Formerly: SmithKline

Beecham Clinical Laboratories,

SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated, 4770

Regent Blvd., Irving, TX 75063, 972–

916–3376/800–526–0947 (Formerly:

Damon Clinical Laboratories, Damon/

MetPath, CORNING Clinical

Laboratories)

Quest Diagnostics Incorporated, 801

East Dixie Ave., Suite 105A, Leesburg,

FL 34748, 352–787–9006x4343

(Formerly: SmithKline Beecham

Clinical Laboratories, Doctors &

Physicians Laboratory)

Quest Diagnostics Incorporated, 400

Egypt Rd., Norristown, PA 19403,

610–631–4600/800–877–7484

(Formerly: SmithKline Beecham

Clinical Laboratories, SmithKline BioScience Laboratories)

Quest Diagnostics Incorporated, 506 E.

State Pkwy., Schaumburg, IL 60173,

800–669–6995/847–885–2010

(Formerly: SmithKline Beecham

Clinical Laboratories, International

Toxicology Laboratories)

Quest Diagnostics Incorporated, 7470

Mission Valley Rd., San Diego, CA

92108–4406, 619–686–3200/800–446–

4728 (Formerly: Nichols Institute,

Nichols Institute Substance Abuse

Testing (NISAT), CORNING Nichols

Institute, CORNING Clinical

Laboratories)

Quest Diagnostics Incorporated, One

Malcolm Ave., Teterboro, NJ 07608,

201–393–5590 (Formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories, CORNING Clinical

Laboratory)

Quest Diagnostics Incorporated, 7600

Tyrone Ave., Van Nuys, CA 91405,

818–989–2520/800–877–2520

(Formerly: SmithKline Beecham

Clinical Laboratories)

San Diego Reference Laboratory, 6122

Nancy Ridge Dr., San Diego, CA

92121, 800–677–7995/858–677–7970

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA

23236, 804–378–9130

Scott & White Drug Testing Laboratory,

600 S. 25th St., Temple, TX 76504,

254–771–8379/800–749–3788

S.E.D. Medical Laboratories, 5601 Office

Blvd., Albuquerque, NM 87109, 505–

727–6300/800–999–5227

South Bend Medical Foundation, Inc.,

530 N. Lafayette Blvd., South Bend,

IN 46601, 219–234–4176

Southwest Laboratories, 2727 W.

Baseline Rd., Tempe, AZ 85283, 602–

438–8507/800–279–0027

Sparrow Health System, Toxicology

Testing Center, St. Lawrence Campus,

1210 W. Saginaw, Lansing, MI 48915,

517–377–0520 (Formerly: St.

Lawrence Hospital & Healthcare

System)

St. Anthony Hospital Toxicology

Laboratory, 1000 N. Lee St.,

Oklahoma City, OK 73101, 405–272–

7052

Federal Register / Vol. 65, No. 212 / Wednesday, November 1, 2000 / Notices 65323

Toxicology & Drug Monitoring

Laboratory, University of Missouri

Hospital & Clinics, 2703 Clark Lane,

Suite B, Lower Level, Columbia, MO

65202, 573–882–1273

Toxicology Testing Service, Inc., 5426

N.W. 79th Ave., Miami, FL 33166,

305–593–2260

UNILAB, 18408 Oxnard St., Tarzana,

CA 91356, 818–996–7300/800–339–

4299 (Formerly: MetWest-BPL

Toxicology Laboratory)

Universal Toxicology Laboratories, LLC,

9930 W. Highway 80, Midland, TX

79706, 915–561–8851/888–953–8851

*The Standards Council of Canada (SCC)

voted to end its Laboratory Accreditation

Program for Substance Abuse (LAPSA)

effective May 12, 1998. Laboratories certified

through that program were accredited to

conduct forensic urine drug testing as

required by U.S. Department of

Transportation (DOT) regulations. As of that

date, the certification of those accredited

Canadian laboratories will continue under

DOT authority. The responsibility for

conducting quarterly performance testing

plus periodic on-site inspections of those

LAPSA-accredited laboratories was

transferred to the U.S. DHHS, with the

DHHS’ National Laboratory Certification

Program (NLCP) contractor continuing to

have an active role in the performance testing

and laboratory inspection processes. Other

Canadian laboratories wishing to be

considered for the NLCP may apply directly

to the NLCP contractor just as U.S.

laboratories do. Upon finding a Canadian

laboratory to be qualified, the DHHS will

recommend that DOT certify the laboratory

(Federal Register, 16 July 1996) as meeting

the minimum standards of the ‘‘Mandatory

Guidelines for Workplace Drug Testing’’ (59

Federal Register, 9 June 1994, Pages 29908–

29931). After receiving the DOT certification,

the laboratory will be included in the

monthly list of DHHS certified laboratories

and participate in the NLCP certification

maintenance program.

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

[FR Doc. 00–27872 Filed 10–31–00; 8:45 am]

BILLING CODE 4160–20–U

DEPARTMENT OF HOUSING AND

URBAN DEVELOPMENT

[Docket No. FR–4561–N–73]

Notice of Submission of Proposed

Information Collection to OMB; LeadBased Paint Hazard Control Grant

Program Data Collection

AGENCY: Office of the Chief Information

Officer, HUD.

ACTION: Notice.

SUMMARY: The proposed information

collection requirement described below

has been submitted to the Office of

Management and Budget (OMB) for

review, as required by the Paperwork

Reduction Act. The Department is

soliciting public comments on the

subject proposal.

DATES: December 1, 2000.

ADDRESSES: Interested persons are

invited to submit comments regarding

this proposal. Comments should refer to

the proposal by name and/or OMB

approval number (2539–0008) and

should be sent to: Joseph F. Lackey, Jr.,

OMB Desk Officer, Office of

Management and Budget, Room 10235,

New Executive Office Building,

Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT:

Wayne Eddins, Reports Management

Officer, Q, Department of Housing and

Urban Development, 451 Seventh Street,

Southwest, Washington, DC 20410; email Wayne_Eddins@HUD.gov;

telephone (202) 708–2374. This is not a

toll-free number. Copies of the proposed

forms and other available documents

submitted to OMB may be obtained

from Mr. Eddins.

SUPPLEMENTARY INFORMATION: The

Department has submitted the proposal

for the collection of information, as

described below, to OMB for review, as

required by the Paperwork Reduction

Act (44 U.S.C. Chapter 35). The Notice

lists the following information: (1) The

title of the information collection

proposal; (2) the office of the agency to

collect the information; (3) the OMB

approval number, if applicable; (4) the

description of the need for the

information and its proposed use; (5)

the agency form number, if applicable;

(6) what members of the public will be

affected by the proposal; (7) how

frequently information submissions will

be required; (8) an estimate of the total

number of hours needed to prepare the

information submission including

number of respondents, frequency of

response, and hours of response; (9)

whether the proposal is new, an

extension, reinstatement, or revision of

an information collection requirement;

and (10) the name and telephone

number of an agency official familiar

with the proposal and of the OMB Desk

Officer for the Department.

This Notice also lists the following

information:

Title of Proposal: Lead-Based Paint

Hazard Control Grant Data Collection.

OMB Approval Number: 2539–0008.

Form Numbers: HUD–96006.

Description of the Need for the

Information and Its Proposed Use: This

data collection is necessary to provide

timely information to HUD regarding

the progress of the grantees

implementation the Lead-Based Paint

Hazard Control Grant Program and to

provide Congress with status reports as

required by statute.—Title X of the

Housing and Community Development

Act of 1992 (PL 102–550).

Frequency of Submission: Quarterly.

Number of

respondents × Frequency ofresponse × Hours perresponse = Burden hours

Reporting Burden ...................................................................... 130 4 12 6,240